HOME Press Releases Cancer/Tumor Profiling Market worth 8.74 Billion USD by 2022



Cancer/Tumor Profiling Market worth 8.74 Billion USD by 2022


The report "Cancer/Tumor Profiling Market by Application (Clinical, Research), Technology (Immunoassay, Hybridization (PCR, In Situ Hybridization, DNA/RNA Microarray), NGS, Mass Spectrometry), Cancer Type (Breast, Lung, Prostate, Colorectal) - Global Forecast to 2022", is projected to reach USD 8.74 Billion by 2022 from USD 5.26 Billion in 2017, at a CAGR of 10.7%. Major factors fueling the growth of the market include increasing number of cancer cases across the globe, the increasing utility of biomarkers, and availability of funding for cancer research. On the other hand, high capital investments and low benefit ratio for biomarkers used in cancer/tumor profiling are expected to limit the cancer/tumor profiling market growth to a certain extent. Factors such as the increasing demand for personalized medicine and point-of-care diagnostic tests in cancer/tumor profiling are expected to offer a wide range of growth opportunities for players in the cancer/tumor profiling market.

                  Request Sample               Request Sample

Browse 67 market data Tables and 32 Figures spread through 155 Pages and in-depth TOC on "Cancer/Tumor Profiling Market by Application (Clinical, Research), Technology (Immunoassay, Hybridization (PCR, In Situ Hybridization, DNA/RNA Microarray), NGS, Mass Spectrometry), Cancer Type (Breast, Lung, Prostate, Colorectal) - Global Forecast to 2022"
https://www.marketsandmarkets.com/Market-Reports/cancer-tumor-profiling-market-1250.html
Early buyers will receive 10% customization on reports.

The breast cancer segment market to hold the largest share during the forecast period

Based on cancer type, the cancer/tumor profile market is categorized into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and other cancer types. In 2017, the breast cancer segment is expected to account for the largest share of the global cancer/tumor profiling market. The largest share of this segment is mainly attributed to the high prevalence of breast cancer over the last few years, increased awareness about breast cancer diagnosis, and increasing research focus on breast cancer.

The NGS segment to register the highest CAGR during the forecast period

Based on technology, the cancer/tumor profile market is categorized into immunoassays, hybridization, NGS, mass spectrometry, and other technologies. The NGS segment is expected to register the highest CAGR during the forecast period. Factors such as advancements in sequencing technologies, growing number of new cancer cases, a wide range of applications, and the preference for personalized medicines (in which this technology has significant applications) are expected to boost the growth of NGS technology in the future.

The research application segment to grow at the highest CAGR during the forecast period

Based on application, the cancer/tumor profiling market is categorized into clinical application and research application. The research application segment is expected to grow at the highest CAGR during the forecast period. Companies are increasingly focusing on the use of biomarkers as biological indicators for the progress of diseases and the effect of therapeutic interventions & drug-induced toxicity.

Asia Pacific to grow at the highest CAGR during the forecast period

Asia Pacific is expected to grow at the highest CAGR during the forecast period. In recent years, the Asia Pacific market for cancer/tumor profiling has witnessed significant growth due to the rising incidence of cancer, increasing demand for better healthcare services in developing economies such as India and China, rising number of contract research organizations (CROs), and increasing focus of international players on emerging markets.

Market Players

The cancer/tumor profiling market is dominated by established players such as Illumina (US), QIAGEN (Netherlands), NeoGenomics Laboratories (US), HTG Molecular Diagnostic (US), and Genomic Health (US).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports